{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T17:10:17Z","timestamp":1784740217855,"version":"3.55.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,21]]},"DOI":"10.7759\/cureus.77769","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T13:33:54Z","timestamp":1737466434000},"source":"Crossref","is-referenced-by-count":2,"title":["Accelerated Coronary Artery Disease in a Patient With Advanced Lung Cancer: Interplay of Cancer, Inflammation, and Treatment Effects"],"prefix":"10.7759","author":[{"given":"Oluwaremilekun","family":"Tolu-Akinnawo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayode E","family":"Ogunniyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","year":"2020","unstructured":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019. a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020, 396:1204-22. 10.1016\/S0140-6736(20)30925-9","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study","volume":"76","author":"Roth GA","year":"2020","unstructured":"Roth GA, Mensah GA, Johnson CO, et al.. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020, 76:2982-3021. 10.1016\/j.jacc.2020.11.010","journal-title":"J Am Coll Cardiol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung H","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021, 71:209-49. 10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.03.001","article-title":"New ACC Global Heart\u00a0Attack Treatment Initiative: improving STEMI care worldwide","volume":"75","author":"Levenson B","year":"2020","unstructured":"Levenson B, Herrera C, Wilson BH. New ACC Global Heart\u00a0Attack Treatment Initiative: improving STEMI care worldwide. J Am Coll Cardiol. 2020, 75:1605-8. 10.1016\/j.jacc.2020.03.001","journal-title":"J Am Coll Cardiol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07487-9","article-title":"Impact of pre-existing cardiovascular disease on treatment patterns and survival outcomes in patients with lung cancer","volume":"20","author":"Batra A","year":"2020","unstructured":"Batra A, Sheka D, Kong S, Cheung WY. Impact of pre-existing cardiovascular disease on treatment patterns and survival outcomes in patients with lung cancer. BMC Cancer. 2020, 20:10.1186\/s12885-020-07487-9","journal-title":"BMC Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/ehjqcco\/qcac016","article-title":"Temporal trends in disease-specific causes of cardiovascular mortality amongst patients with cancer in the USA between 1999 and 2019","volume":"9","author":"Raisi-Estabragh Z","year":"2022","unstructured":"Raisi-Estabragh Z, Kobo O, Freeman P, et al.. Temporal trends in disease-specific causes of cardiovascular mortality amongst patients with cancer in the USA between 1999 and 2019. Eur Heart J Qual Care Clin Outcomes. 2022, 9:54-63. 10.1093\/ehjqcco\/qcac016","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1539","article-title":"Cancer and heart disease: associations and relations","volume":"21","author":"de Boer RA","year":"2019","unstructured":"de Boer RA, Meijers WC, van der Meer P, van Veldhuisen DJ. Cancer and heart disease: associations and relations. Eur J Heart Fail. 2019, 21:1515-25. 10.1002\/ejhf.1539","journal-title":"Eur J Heart Fail"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.10.9777","article-title":"American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects","volume":"25","author":"Carver JR","year":"2007","unstructured":"Carver JR, Shapiro CL, Ng A, et al.. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol. 2007, 25:3991-4008. 10.1200\/JCO.2007.10.9777","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.0000163635.62927.34","article-title":"Adipose tissue, inflammation, and cardiovascular disease","volume":"96","author":"Berg AH","year":"2005","unstructured":"Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res. 2005, 96:939-49. 10.1161\/01.RES.0000163635.62927.34","journal-title":"Circ Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0149","article-title":"Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe","volume":"15","author":"Aggarwal BB","year":"2009","unstructured":"Aggarwal BB, Vijayalekshmi RV, Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res. 2009, 15:425-30. 10.1158\/1078-0432.CCR-08-0149","journal-title":"Clin Cancer Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2013.08.014","article-title":"Molecular mechanisms underlying chronic inflammation-associated cancers","volume":"345","author":"Wu Y","year":"2014","unstructured":"Wu Y, Antony S, Meitzler JL, Doroshow JH. Molecular mechanisms underlying chronic inflammation-associated cancers. Cancer Lett. 2014, 345:164-73. 10.1016\/j.canlet.2013.08.014","journal-title":"Cancer Lett"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.07.037","article-title":"Cardiovascular effects of exposure to cigarette smoke and electronic cigarettes: clinical perspectives from the prevention of cardiovascular disease section leadership council and early career councils of the American College of Cardiology","volume":"66","author":"Morris PB","year":"2015","unstructured":"Morris PB, Ference BA, Jahangir E, et al.. Cardiovascular effects of exposure to cigarette smoke and electronic cigarettes: clinical perspectives from the prevention of cardiovascular disease section leadership council and early career councils of the American College of Cardiology. J Am Coll Cardiol. 2015, 66:1378-91. 10.1016\/j.jacc.2015.07.037","journal-title":"J Am Coll Cardiol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000133187.74800.B9","article-title":"Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management","volume":"109","author":"Yeh ET","year":"2004","unstructured":"Yeh ET, Tong AT, Lenihan DJ, et al.. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation. 2004, 109:3122-31. 10.1161\/01.CIR.0000133187.74800.B9","journal-title":"Circulation"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.8.17.9322","article-title":"Mirk\/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cells","volume":"8","author":"Gao J","year":"2009","unstructured":"Gao J, Zheng Z, Rawal B, Schell MJ, Bepler G, Haura EB. Mirk\/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cells. Cancer Biol Ther. 2009, 8:1671-9. 10.4161\/cbt.8.17.9322","journal-title":"Cancer Biol Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000180","article-title":"Self-reported cardiovascular disease and the risk of lung cancer, the HUNT study","volume":"9","author":"Hatlen P","year":"2014","unstructured":"Hatlen P, Langhammer A, Carlsen SM, Salvesen \u00d8, Amundsen T. Self-reported cardiovascular disease and the risk of lung cancer, the HUNT study. J Thorac Oncol. 2014, 9:940-6. 10.1097\/JTO.0000000000000180","journal-title":"J Thorac Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1053\/j.jvca.2017.04.033","article-title":"Lung cancer and risk of cardiovascular disease: a meta-analysis of cohort studies","volume":"32","author":"Yuan M","year":"2018","unstructured":"Yuan M, Li QG. Lung cancer and risk of cardiovascular disease: a meta-analysis of cohort studies. J Cardiothorac Vasc Anesth. 2018, 32:25-7. 10.1053\/j.jvca.2017.04.033","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.035516","article-title":"Synergistic opportunities in the interplay between cancer screening and cardiovascular disease risk assessment: together we are stronger","volume":"138","author":"Handy CE","year":"2018","unstructured":"Handy CE, Quispe R, Pinto X, et al.. Synergistic opportunities in the interplay between cancer screening and cardiovascular disease risk assessment: together we are stronger. Circulation. 2018, 138:727-34. 10.1161\/CIRCULATIONAHA.118.035516","journal-title":"Circulation"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.020406","article-title":"Shared risk factors in cardiovascular disease and cancer","volume":"133","author":"Koene RJ","year":"2016","unstructured":"Koene RJ, Prizment AE, Blaes A, Konety SH. Shared risk factors in cardiovascular disease and cancer. Circulation. 2016, 133:1104-14. 10.1161\/CIRCULATIONAHA.115.020406","journal-title":"Circulation"},{"key":"ref19","unstructured":"Racial and ethnic disparities. (2024). https.\/\/www.lung.org\/research\/state-of-lung-cancer\/racial-and-ethnic-disparities."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.18632\/aging.102301","article-title":"Prevalence and prognosis significance of cardiovascular disease in cancer patients: a population-based study","volume":"11","author":"Liu D","year":"2019","unstructured":"Liu D, Ma Z, Yang J, et al.. Prevalence and prognosis significance of cardiovascular disease in cancer patients: a population-based study. Aging (Albany NY). 2019, 11:7948-60. 10.18632\/aging.102301","journal-title":"Aging (Albany NY)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9051268","article-title":"Cardiovascular complications of systemic therapy in non-small-cell lung cancer","volume":"9","author":"Zaborowska-Szmit M","year":"2020","unstructured":"Zaborowska-Szmit M, Krzakowski M, Kowalski DM, Szmit S. Cardiovascular complications of systemic therapy in non-small-cell lung cancer. J Clin Med. 2020, 9:10.3390\/jcm9051268","journal-title":"J Clin Med"},{"key":"ref22","article-title":"Phase II clinical trial of weekly administration of VP-16-213 in small cell bronchogenic carcinoma","volume":"61","author":"Cohen MH","year":"1977","unstructured":"Cohen MH, Broder LE, Fossieck BE, Ihde DC, Minna JD. Phase II clinical trial of weekly administration of VP-16-213 in small cell bronchogenic carcinoma. Cancer Treat Rep. 1977, 61:489-90.","journal-title":"Cancer Treat Rep"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/s0936-6555(05)80819-2","article-title":"Etoposide-related myocardial infarction","volume":"7","author":"Airey CL","year":"1995","unstructured":"Airey CL, Dodwell DJ, Joffe JK, Jones WG. Etoposide-related myocardial infarction. Clin Oncol. 1995, 7:10.1016\/s0936-6555(05)80819-2","journal-title":"Clin Oncol"},{"key":"ref24","article-title":"Non-Q-wave myocardial infarction associated with bleomycin and etoposide chemotherapy","volume":"12","author":"Schwarzer S","year":"1991","unstructured":"Schwarzer S, Eber B, Greinix H, Lind P. Non-Q-wave myocardial infarction associated with bleomycin and etoposide chemotherapy. Eur Heart J. 1991, 12:748-50.","journal-title":"Eur Heart J"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.54.1.25","article-title":"Myocardial infarction in patients undergoing noncardiac surgery","volume":"54","author":"Becker RC","year":"1987","unstructured":"Becker RC, Underwood DA. Myocardial infarction in patients undergoing noncardiac surgery. Cleve Clin J Med. 1987, 54:25-8. 10.3949\/ccjm.54.1.25","journal-title":"Cleve Clin J Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.40089","article-title":"Case of ST-elevation myocardial infarction in a 32-year-old male receiving bleomycin, etoposide, and cisplatin chemotherapy for embryonal carcinoma","volume":"15","author":"Bassil E","year":"2023","unstructured":"Bassil E, Singh H, Ahmed O, Parikh S. Case of ST-elevation myocardial infarction in a 32-year-old male receiving bleomycin, etoposide, and cisplatin chemotherapy for embryonal carcinoma. Cureus. 2023, 15:10.7759\/cureus.40089","journal-title":"Cureus"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.7324\/JAPS.2018.8519","article-title":"Cisplatin-etoposide induced myocardial infarction in a patient with small cell carcinoma","volume":"8","author":"Katta S","year":"2018","unstructured":"Katta S, Chauhan S, Singh A, Shetty PN, Kareem H, Devasia T. Cisplatin-etoposide induced myocardial infarction in a patient with small cell carcinoma. J App Pharm Sci. 2018, 8:10.7324\/JAPS.2018.8519","journal-title":"J App Pharm Sci"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.38.436","article-title":"Vasospastic angina likely related to cisplatin-containing chemotherapy and thoracic irradiation for lung cancer","volume":"38","author":"Fukuda M","year":"1999","unstructured":"Fukuda M, Oka M, Itoh N, Sakamoto T, Mori H, Hayakawa A, Kohno S. Vasospastic angina likely related to cisplatin-containing chemotherapy and thoracic irradiation for lung cancer. Intern Med. 1999, 38:436-8. 10.2169\/internalmedicine.38.436","journal-title":"Intern Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00196","article-title":"Characterization of cardiovascular alterations induced by different chronic cisplatin treatments","volume":"8","author":"Herrad\u00f3n E","year":"2017","unstructured":"Herrad\u00f3n E, Gonz\u00e1lez C, Uranga JA, Abalo R, Mart\u00edn MI, L\u00f3pez-Miranda V. Characterization of cardiovascular alterations induced by different chronic cisplatin treatments. Front Pharmacol. 2017, 8:10.3389\/fphar.2017.00196","journal-title":"Front Pharmacol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2013.09.010","article-title":"Cancer survivorship: cardiotoxic therapy in the adult cancer patient; cardiac outcomes with recommendations for patient management","volume":"40","author":"Steingart RM","year":"2013","unstructured":"Steingart RM, Yadav N, Manrique C, Carver JR, Liu J. Cancer survivorship: cardiotoxic therapy in the adult cancer patient; cardiac outcomes with recommendations for patient management. Semin Oncol. 2013, 40:690-708. 10.1053\/j.seminoncol.2013.09.010","journal-title":"Semin Oncol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.eurheartj.a062542","article-title":"Acute vascular toxicity after combination chemotherapy with cisplatin, vinblastine, and bleomycin for testicular cancer","volume":"9","author":"Stefenelli T","year":"1988","unstructured":"Stefenelli T, Kuzmits R, Ulrich W, Glogar D. Acute vascular toxicity after combination chemotherapy with cisplatin, vinblastine, and bleomycin for testicular cancer. Eur Heart J. 1988, 9:552-6. 10.1093\/oxfordjournals.eurheartj.a062542","journal-title":"Eur Heart J"},{"key":"ref32","article-title":"Acute myocardial infarction induced by lung cancer chemotherapy with cisplatin and etoposide. [Article in Japanese]","volume":"17","author":"Tsutsumi T","year":"1990","unstructured":"Tsutsumi T, Ozawa Y, Kawakami A, Fujii H, Asamoto H. Acute myocardial infarction induced by lung cancer chemotherapy with cisplatin and etoposide. [Article in Japanese]. Gan To Kagaku Ryoho. 1990, 17:413-7.","journal-title":"Gan To Kagaku Ryoho"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.5604\/20828691.1189719","article-title":"Cisplatin-induced cardiotoxicity - two case reports","volume":"4","author":"Sawant SP","year":"2015","unstructured":"Sawant SP, Prakruthi J, Daddi AD, Ghosh J, Joshi A, Dhir AA. Cisplatin-induced cardiotoxicity - two case reports. OncoReview. 2015, 4:145-50. 10.5604\/20828691.1189719","journal-title":"OncoReview"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.1990.5.2.112","article-title":"Electrocardiographic changes simulating acute myocardial infarction or ischemia associated with combination chemotherapy with etoposide, cisplatin, and 5-fluorouracil","volume":"5","author":"Lee KH","year":"1990","unstructured":"Lee KH, Lee JS, Kim SH. Electrocardiographic changes simulating acute myocardial infarction or ischemia associated with combination chemotherapy with etoposide, cisplatin, and 5-fluorouracil. Korean J Intern Med. 1990, 5:112-7. 10.3904\/kjim.1990.5.2.112","journal-title":"Korean J Intern Med"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13957","article-title":"Efficacy and dose of afatinib in patients with non-small cell lung cancer after failure of prior gefitinib or erlotinib treatment","volume":"12","author":"Choi H","year":"2021","unstructured":"Choi H, Lee JK, Oh HJ, et al.. Efficacy and dose of afatinib in patients with non-small cell lung cancer after failure of prior gefitinib or erlotinib treatment. Thorac Cancer. 2021, 12:1598-604. 10.1111\/1759-7714.13957","journal-title":"Thorac Cancer"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1258991","article-title":"Cardiovascular disease and lung cancer","volume":"14","author":"de Jesus M","year":"2024","unstructured":"de Jesus M, Chanda A, Grabauskas T, Kumar M, Kim AS. Cardiovascular disease and lung cancer. Front Oncol. 2024, 14:10.3389\/fonc.2024.1258991","journal-title":"Front Oncol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2019.11.013","article-title":"Immune checkpoint inhibitor-related adverse cardiovascular events in patients with lung cancer","volume":"1","author":"Chitturi KR","year":"2019","unstructured":"Chitturi KR, Xu J, Araujo-Gutierrez R, et al.. Immune checkpoint inhibitor-related adverse cardiovascular events in patients with lung cancer. JACC CardioOncol. 2019, 1:182-92. 10.1016\/j.jaccao.2019.11.013","journal-title":"JACC CardioOncol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.049981","article-title":"Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque","volume":"142","author":"Drobni ZD","year":"2020","unstructured":"Drobni ZD, Alvi RM, Taron J, et al.. Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque. Circulation. 2020, 142:2299-311. 10.1161\/CIRCULATIONAHA.120.049981","journal-title":"Circulation"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab618","article-title":"Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis","volume":"42","author":"Dolladille C","year":"2021","unstructured":"Dolladille C, Akroun J, Morice PM, et al.. Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis. Eur Heart J. 2021, 42:4964-77. 10.1093\/eurheartj\/ehab618","journal-title":"Eur Heart J"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.027288","article-title":"Cardiac adverse events associated with chemo-radiation versus chemotherapy for resectable stage III non-small-cell lung cancer: a surveillance, epidemiology and end results-medicare study","volume":"11","author":"Herbach E","year":"2022","unstructured":"Herbach E, O'Rorke MA, Carnahan RM, et al.. Cardiac adverse events associated with chemo-radiation versus chemotherapy for resectable stage III non-small-cell lung cancer: a surveillance, epidemiology and end results-medicare study. J Am Heart Assoc. 2022, 11:10.1161\/JAHA.122.027288","journal-title":"J Am Heart Assoc"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2008.01.002","article-title":"The diagnosis and management of cardiovascular disease in cancer patients","volume":"33","author":"Yusuf SW","year":"2008","unstructured":"Yusuf SW, Razeghi P, Yeh ET. The diagnosis and management of cardiovascular disease in cancer patients. Curr Probl Cardiol. 2008, 33:163-96. 10.1016\/j.cpcardiol.2008.01.002","journal-title":"Curr Probl Cardiol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000066691.52789.BE","article-title":"Reactive oxygen species are involved in smoking-induced dysfunction of nitric oxide biosynthesis and upregulation of endothelial nitric oxide synthase: an in vitro demonstration in human coronary artery endothelial cells","volume":"107","author":"Barua RS","year":"2003","unstructured":"Barua RS, Ambrose JA, Srivastava S, DeVoe MC, Eales-Reynolds LJ. Reactive oxygen species are involved in smoking-induced dysfunction of nitric oxide biosynthesis and upregulation of endothelial nitric oxide synthase: an in vitro demonstration in human coronary artery endothelial cells. Circulation. 2003, 107:2342-7. 10.1161\/01.CIR.0000066691.52789.BE","journal-title":"Circulation"},{"key":"ref43","article-title":"Which major atherosclerosis risk factors represents the extent of coronary artery disease?","volume":"7","author":"Sadeghi M","year":"2012","unstructured":"Sadeghi M, Pourmand K, Sanei H, Heidari R, Talaei M. Which major atherosclerosis risk factors represents the extent of coronary artery disease?. ARYA Atherosclerosis. 2012, 7:63-9.","journal-title":"ARYA Atherosclerosis"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2003.12.047","article-title":"The pathophysiology of cigarette smoking and cardiovascular disease: an update","volume":"43","author":"Ambrose JA","year":"2004","unstructured":"Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol. 2004, 43:1731-7. 10.1016\/j.jacc.2003.12.047","journal-title":"J Am Coll Cardiol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000002478","article-title":"Association between secondhand smoke exposure and hypertension: nearly as large as smoking","volume":"38","author":"Skipina TM","year":"2020","unstructured":"Skipina TM, Soliman EZ, Upadhya B. Association between secondhand smoke exposure and hypertension: nearly as large as smoking. J Hypertens. 2020, 38:1899-908. 10.1097\/HJH.0000000000002478","journal-title":"J Hypertens"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.2337\/db12-0418","article-title":"Novel and reversible mechanisms of smoking-induced insulin resistance in humans","volume":"61","author":"Bergman BC","year":"2012","unstructured":"Bergman BC, Perreault L, Hunerdosse D, Kerege A, Playdon M, Samek AM, Eckel RH. Novel and reversible mechanisms of smoking-induced insulin resistance in humans. Diabetes. 2012, 61:3156-66. 10.2337\/db12-0418","journal-title":"Diabetes"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa460","article-title":"Effects of tobacco cigarettes, e-cigarettes, and waterpipe smoking on endothelial function and clinical outcomes","volume":"41","author":"M\u00fcnzel T","year":"2020","unstructured":"M\u00fcnzel T, Hahad O, Kuntic M, Keaney JF, Deanfield JE, Daiber A. Effects of tobacco cigarettes, e-cigarettes, and waterpipe smoking on endothelial function and clinical outcomes. Eur Heart J. 2020, 41:4057-70. 10.1093\/eurheartj\/ehaa460","journal-title":"Eur Heart J"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrrev.2021.108365","article-title":"Relationships among smoking, oxidative stress, inflammation, macromolecular damage, and cancer","volume":"787","author":"Caliri AW","year":"2021","unstructured":"Caliri AW, Tommasi S, Besaratinia A. Relationships among smoking, oxidative stress, inflammation, macromolecular damage, and cancer. Mutat Res Rev Mutat Res. 2021, 787:10.1016\/j.mrrev.2021.108365","journal-title":"Mutat Res Rev Mutat Res"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer","volume":"420","author":"Coussens LM","year":"2002","unstructured":"Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002, 420:860-7. 10.1038\/nature01322","journal-title":"Nature"},{"key":"ref50","unstructured":"Chronic inflammation. (2015). https.\/\/www.cancer.gov\/about-cancer\/causes-prevention\/risk\/chronic-inflammation."},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.03.010","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular\u00a0disease: a report of the American College of Cardiology\/American Heart Association Task\u00a0Force\u00a0on\u00a0clinical practice guidelines","volume":"74","author":"Arnett DK","year":"2019","unstructured":"Arnett DK, Blumenthal RS, Albert MA, et al.. 2019 ACC\/AHA guideline on the primary prevention of cardiovascular\u00a0disease: a report of the American College of Cardiology\/American Heart Association Task\u00a0Force\u00a0on\u00a0clinical practice guidelines. J Am Coll Cardiol. 2019, 74:177-232. 10.1016\/j.jacc.2019.03.010","journal-title":"J Am Coll Cardiol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2015.01.006","article-title":"Cardiovascular comorbidities and survival of lung cancer patients: medicare data based analysis","volume":"88","author":"Kravchenko J","year":"2015","unstructured":"Kravchenko J, Berry M, Arbeev K, Lyerly HK, Yashin A, Akushevich I. Cardiovascular comorbidities and survival of lung cancer patients: medicare data based analysis. Lung Cancer. 2015, 88:85-93. 10.1016\/j.lungcan.2015.01.006","journal-title":"Lung Cancer"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline","volume":"35","author":"Armenian SH","year":"2017","unstructured":"Armenian SH, Lacchetti C, Barac A, et al.. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017, 35:893-911. 10.1200\/JCO.2016.70.5400","journal-title":"J Clin Oncol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon AR","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, et al.. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022, 43:4229-361. 10.1093\/eurheartj\/ehac244","journal-title":"Eur Heart J"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","volume":"31","author":"Curigliano G","year":"2020","unstructured":"Curigliano G, Lenihan D, Fradley M, et al.. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020, 31:171-90. 10.1016\/j.annonc.2019.10.023","journal-title":"Ann Oncol"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0040","article-title":"Myocarditis surveillance in patients with advanced melanoma on combination immune checkpoint inhibitor therapy: the Memorial Sloan Kettering Cancer Center experience","volume":"24","author":"Chuy LK","year":"2019","unstructured":"Chuy LK, Oikonomou EK, Postow MA, et al.. Myocarditis surveillance in patients with advanced melanoma on combination immune checkpoint inhibitor therapy: the Memorial Sloan Kettering Cancer Center experience. Oncologist. 2019, 24:196-7. 10.1634\/theoncologist.2019-0040","journal-title":"Oncologist"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/335090-accelerated-coronary-artery-disease-in-a-patient-with-advanced-lung-cancer-interplay-of-cancer-inflammation-and-treatment-effects","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T13:33:59Z","timestamp":1737466439000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/335090-accelerated-coronary-artery-disease-in-a-patient-with-advanced-lung-cancer-interplay-of-cancer-inflammation-and-treatment-effects"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,21]]},"references-count":56,"URL":"https:\/\/doi.org\/10.7759\/cureus.77769","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,21]]}}}